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Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers principally because of early invasion and
metastasis. The epidermal growth factor receptor (EGFR) is essential for PDAC development even in the presence of
Kras, but its inhibition with erlotinib gives only amodest clinical response, making the discovery of novel EGFR targets
of critical interest. Here, we revealed by mining a human pancreatic gene expression database that the metastasis
promoter Na+/H+ exchanger (NHE1) associateswith the EGFR in PDAC. In human PDAC cell lines, we confirmed that
NHE1 drives both basal and EGF-stimulated three-dimensional growth and early invasion via invadopodial extracellular
matrix digestion. EGF promoted the complexing of EGFR with NHE1 via the scaffolding protein Na+/H+ exchanger
regulatory factor 1, engaging EGFR in a negative transregulatory loop that controls the extent and duration of EGFR
oncogenic signaling and stimulates NHE1. The specificity of NHE1 for growth or invasion depends on the segregation
of the transient EGFR/Na+/H+ exchanger regulatory factor 1/NHE1 signaling complex into dimeric subcomplexes in
different lipid raftlike membrane domains. This signaling complex was also found in tumors developed in orthotopic
mice. Importantly, the specific NHE1 inhibitor cariporide reduced both three-dimensional growth and invasion
independently of PDAC subtype and synergistically sensitized these behaviors to low doses of erlotinib.
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Pancreatic ductal adenocarcinoma (PDAC) is one of the most
deadly cancers, having a 5-year survival rate less than 5%, as
even patients with apparently localized resectable tumors have
occult distant micrometastases at the time of surgery [1].
Indeed, PDAC cell invasion occurs very early in the disease
maybe even before the formation of an identifiable primary
tumor [2]. Therefore, although surgery remains the corner-
stone of cure, the need for adjuvant treatment modalities is of
critical importance [3].
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important mediators of desmoplastic stroma production [4], PDAC
invasive growth [5], and resistance to apoptosis [6]. Accordingly,
overexpression or active mutants of the EGF receptor (EGFR)
correlate with distant metastases, resistance to chemotherapeutics,
and decreased patient survival [7]. Indeed, in both PDAC tumors and
cell lines, the EGFR is the principal activated receptor [8].
Furthermore, PDAC tumors and cell lines can be divided into
“classical” and “quasimesenchymal” (QM-PDAC) subtypes, with the
QM-PDAC subtype having far worse survival rates [9] and being less
dependent on Kras but responsive to anti-EGFR treatment with the
EGFR tyrosine kinase inhibitor erlotinib (OSI-774, Tarceva) [9].
This implies that PDAC cells, differently from other cancer types also
dependent on mutant KRAS, still use the EGFR [10–12].
Accordingly, the current FDA-approved therapy for the first-line
treatment of patients with locally advanced or metastatic PDAC
combines chemotherapy with erlotinib but with limited survival
benefits [13]. This small survival advantage, however, clearly points to
the need for further research to identify agents that will significantly
boost erlotinib’s treatment efficacy. The interaction of EGFR with the
multiple signaling nodes that regulate the different hallmarks of
metastatic progression suggests that a combination of an EGFR inhibitor
and other molecular targeted agents may offer an efficient approach to
controlling PDAC metastasis and/or local invasion. In this respect,
important strategies for identifying these agents are to determine 1) the
key proteins involved in regulating EGFR expression and functional
dynamics and 2) the principal downstream effectors of its function.
The scaffolding protein Na+/H+ exchanger regulatory factor 1
(NHERF1; SLC9A3R) regulates both EGFR trafficking and expression
in breast [14] and biliary cancer [15]. TheNa+/H+ exchanger isoform 1
(NHE1; SLC9A1), one of the principal drivers of metastasis, is an
important downstream effector of EGFR-driven progression [16].
Furthermore, in breast cancer cells, the inhibition of the NHE1 during
the administration of various chemotherapeutic drugs [17] synergisti-
cally potentiates their antineoplastic effects, supporting the hypothesis
that a combination therapy targeting both NHE1 and EGFR in PDAC
may increase their individual antitumor activity. Although PDAC cell
lines express NHE1, its role and dynamics in transducing the EGFR
neoplastic signal in PDAC are still unknown.
We demonstrate that in PDAC exists a novel prometastatic
protein-protein signaling complex centered around EGFR,
NHERF1, and NHE1. The EGFR and NHERF1 are engaged in a
proteasome-dependent, reciprocal feedback regulatory loop in which
NHERF1 and EGFR interact to regulate their expression levels and
functions. This provides a stimulatory signal for NHE1 activity,
which promotes increased invadopodia proteolytic activity, enhanced
local invasion, and three-dimensional (3D) growth of multicellular
tumor spheroids. In line with this, subthreshold concentrations of the
NHE1 inhibitor cariporide sensitized the cells to erlotinib,
determining a synergistic block of 3D colony growth and invasive
capacity. Altogether, these data demonstrate the need to repurpose
inhibitors of NHE1, such as cariporide, for use in the oncological
context and especially in treatment of PDAC [18].
Materials and Methods
Cell Culture
Experiments were performed on well-established human pancreatic
cancer cell lines: PANC-1, BXPC3, MiaPaCa-2, and CAPAN-2. Allcells were kept at 37°C in humidified air containing 5% CO2. Panc-1
cells were grown in bicarbonate-buffered Dulbecco's minimal
essential medium (pH 7.4). All other cells were cultured in
bicarbonate-buffered RPMI 1640 medium (pH 7.4). Media were
always supplemented with 10% fetal calf serum.
3D growth, In Vitro Invasion, Invadopodial Extracellular
Matrix (ECM) Proteolysis, and Migration Assays
The details of the methods for these assays for each cell line are
described in the Supplemental Methods.
Immunofluorescence, Coimmunoprecipitation, and Immunoblot
Analysis
Interactions of NHERF1 with EGFR and NHE1 were analyzed in
PANC-1 cells transiently transfected with WT-NHERF1 or the
respective empty vector and stimulated or not with EGF for the
indicated times. These assays were then performed as described in
Supplemental Methods.
Orthotopic Implantation ofHumanPancreatic TumorCell Lines
and Immunohistofluorescent Staining of Surgical Specimens
All experiment were performed in severe combined immunodefi-
cient mice, strain C.B-17/Ztm-scid of both sexes or nude mice, strain
NMRI-Fox1 nu/nu and were performed according to protocols
approved by the institutional animal use committee and in
accordance with the Declaration of Helsinki protocols. Detailed
protocols can be found in Supplementary Methods.
Data Mining from Gene Expression Data
The potential contribution of NHE1 in EGFR function in PDAC
was explored using the ExploratoryGeneAssociationNetworks (EGAN)
program with a Microarray U133 A/B Affymetrix GeneChip data set
derived from mRNA extracted from patients who had undergone
pancreatic surgery in the University Hospitals of Kiel and Dresden,
Germany, and from a series of pancreatic tumor, normal, and stellate cell
lines [19]. Full details are described in Supplementary Methods.
Statistical Procedures
Data correspond to at least three independent experiments, each of
which was done in triplicate. Results are presented as means ± standard
error. The data for each condition were subject to analysis of variance
followed by Dunnet post hoc test when comparing three or more
conditions or evaluated using Student’s t test when comparing only two
conditions. Significant differences were considered with values ofP b .05.
The results of single and combined treatments with erlotinib and
cariporide on 3D growth were analyzed according to published methods
[20] and are described in more detail in Supplemental Methods.Results
NHE1 Is Associated with EGFR in PDAC and Is a Major
EGFR-Driven pHi Regulator
To explore the potential contribution of NHE1 in EGFR function
in PDAC, we first used the EGAN (UCSF) program to interrogate a
Microarray U133 A/B Affymetrix GeneChip database derived from
mRNA extracted from microdissected patient tissues including
pancreatic tumor and normal epithelium, stromal tissue, and stromal
chronic pancreatitis specimens and from a set of pancreatic tumor,
normal, and stellate cell lines [19]. As shown in the EGAN-produced
interactome map (Figure 1A), data mining of a normal and PDAC
Figure 1. NHE1 is associated with EGFR in PDAC and is the major EGFR-driven pHi regulator. (A) Gene expression profiles of
microdissected PDAC and pancreatic tumor, normal, and stellate cell lines using high-density DNA microarray were analyzed with the
EGAN program for association nodes in a subset of ion transporter proteins and signal transduction molecules. The length of a
connection reflects its strength. (B) RepresentativeWestern blots showing the relative expression of NHE1 (100 and 115 kDa) and EGFR/p
(Y1173)-EGFR in the four PDAC cell lines. β-Actin loading controls. See also Figure S1. (C) EGF stimulates NHE1 activity in the four PDAC
cell lines. Error bars, ±SEM, unpaired Student’s t test. *P b .05, **P b .01, and ***P b .001 compared with the control cells for each line
(n = 5). Cariporide, 500 nM. See also Figure S2.
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(SLC9A1), indicating that NHE1 has a potentially important role in
transducing the EGFR signal in PDAC.
To verify if NHE1 is an effector of EGFR in driving PDAC, we
measured the expression levels of NHE1 and the EGFR and their role
in driving a series of metastatic phenotypes in a panel of PDAC
human cell lines with different metastatic ability and pertaining to
different PDAC subtypes: classical—CAPAN-2, BXPC3 and QM—
PANC-1, MiaPaCa-2 [9]. We first verified if these reported
malignant patterns are expressed in an in vivo mouse model closely
resembling the human clinical course where the above PDAC cell
lines were orthotopically implantated in the healthy pancreas [21,22].
All cell lines infiltrated the normal pancreatic tissue, forming a
localized tumor with the following average primary tumor growth rate
(in mm3 per day: MiaPaCa-2 = 12.9, PANC-1 = 5.3, BXPC3 = 3.6,
and CAPAN-2 = 0.41), but only MiaPaCa-2, PANC-1, and BXPC3
had disseminated metastases as summarized in Figure S1 and Table S1.
Further, MiaPaCa-2 developed more than 10, PANC-1 3 to 10, and
BxPC3 1 to 3 disseminated mesentery metastases, respectively. These
translated into much heavier metastatic loads for PANC-1 and
especially MiaPaCa-2.
Western blotting (Figure 1B) revealed that, in basal conditions, all
four PDAC cell lines expressed both the 100-kDa NHE1 band and
EGFR, and all, except BXPC3, had different levels of posttranscrip-
tional modification of both NHE1 (band of approximately 115 kDa),consistent with its increased phosphorylation and activity [16,23],
and EGFR phosphorylated at Tyr1173 [p(Y1173-EGFR)]. Further-
more, experiments of pHi recovery activity plus or minus EGF and in
the absence or presence of 500 nM of the highly selective inhibitor of
NHE1 cariporide [16] demonstrated that EGF stimulated NHE1
activity in all four cell lines, which can result in an increased
extracellular acidification [24]. Importantly, NHE1 played an
important role in regulating both basal and EGF-stimulated pHi
(Figure 1C, typical experiments shown in Figure S2) with the
following scale: MiaPaCa-2NPANC-1NBXPC3NCAPAN-2.NHE1 Activity Plays an Important Role in Basal and
EGFR-Driven Metastatic Phenotypes
EGF Promotes NHE1-Dependent Colony Formation in 3D
Matrigel Culture
To analyze the ability of cells to grow in an anchorage-independent
manner in 3D semisolid media (ECM scaffolds) [25], we dispersed
cells of each cell line into drops of 7% Matrigel in the presence or
absence of EGF and/or cariporide. As shown in Figure 2A, the
different cell lines had quite different basal and EGF-stimulated
colony formation dynamics and shapes consistent with their reported
malignant potential and subtype gene signatures [9]. The classical
subtypes, CAPAN-2 and BXPC3, were the slowest to form colonies
(Figure 2, A and B), and they formed the most regular, spherical
Figure 2. NHE1 drives basal and EGF-driven 3D colony growth and invasive behaviors. (A) Representative images of colonies from the four
PDACcell lines entrapped in 7%Matrigel plus/minus 100ng/ml EGFandplus/minus10μMcariporide. Imageswere taken atdifferent days after
plating (indicated to the right of images) because of the large differences in colony growth rate. Scale bar, 200 μm. (B) Colony growth rates as
increase in colony volume per day calculated in ImageJ. Mean± SEM, unpaired Student’s t test. *P b .01, **P b .001, and ***P b .0001 (n = 5)
comparedwith the control cells and ††P b .001 and †††P b .0001 compared to the respective EGF cells for each line. (C) Colony circularity index
measured and calculated in ImageJ.Mean± SEM, unpaired Student’s t test. *P b .01, **P b .001, and ***P b .0001 comparedwith the control
cells and ††P b .001 and †††P b .0001 compared to the respective EGF cells for each line. (D) Invasion across a Matrigel layer in Boyden
chambers. Error bars, ± SEM. *P b .01, **P b .001, and ***P b .0001 comparedwith the control cells and †P b .01, ††P b .001, and †††P b .0001
compared to the respective EGF cells (n = 3). (E) Invadopodia focal ECM proteolysis in PANC-1 cells. Representative images show focal ECM
proteolysis (green) and actin immunofluorescence (red). The insets show enlarged views of the boxed regions in which F-actin dots colocalize
with focal fluorescence (arrows) released after the cells had digested the ECM. Scale bars, 20 μm for micrographs, 10 μm for inset. See
also Figure S3. (F) Quantification of the invadopodia focal digestion activity in response to cariporide, EGF, or their combination; error
bars, ± SEM. *P b .01 and **P b .01 compared with the control cells and †P b .01, ††P b .001, and †††P b .0001 compared to the respective
EGF cells (n = 5). (G) Motility expressed as total distance traveled (translocation). Error bars, ± SEM. *P b .05, **P b .01, and ***P b .001
compared with the control cells and †P b .05, ††P b .001, and †††P b .0001 compared to the respective EGF cells (n = 8-11 experiments). See
also Figure S4.
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respectively). In contrast, the aggressive QM-PDAC cell lines, PANC-
1 and MiaPaCa-2, had greater basal growth rates (Figure 2, A and B),
with MiaPaCa-2 forming colonies in the least time (2-3 days) and
PANC-1 slightly slower (5 days). Moreover, both cell lines formed
basal colonies that were irregular (Figure 2C; basal circularity index
of 0.82 and 0.87, respectively) and showed both a high dependency
on EGF stimulation and sensitivity to NHE1 inhibition by
cariporide.
EGF Promotes NHE1-Dependent Invasion, Invadopodia
ECM Proteolysis, and Motility
Another key feature driving malignant PDAC progression is their
strong and early tendency to spread into surrounding tissues [2], and
activation of the EGFR pathway is associated with increased tumor
invasiveness in PDAC cells [26]. In several cancer cell types, cell
invasive capacity is tightly associated with the activity of the NHE1,
and specific inhibition of the NHE1 effectively blocks motility and
invasion (for reviews, [27]. To determine if activation of EGFR
stimulates invasion via NHE1, we analyzed PDAC cell invasive
capacity before and after EGF treatment with and without 1 μM
cariporide. As seen in Figure 2D, PDAC cell invasion increased by
approximately 2-fold and 1.5-fold, respectively, in PANC-1 and
MiaPaCa-2 cells after 24 hours of EGF, and both basal and EGF-
stimulated invasions were reduced by approximately 50% by 1 μM
cariporide. Whereas BXPC3 and CAPAN-2 cells exhibited reduced
basal invasion, EGF stimulated their invasion and cariporide
inhibited both basal and EGF-activated invasions. These data
demonstrate that although there are large differences in the basal
invasive capacity of the cell lines and in their relative sensitivity to
EGF, both basal and EGF-stimulated invasions are highly dependent
on NHE1 activity in all the cell lines.
Highly invasive cancer cells digest the ECM by invadopodia (for
reviews, see [28,29], and NHE1 activity is absolutely necessary for
invadopodia formation and function [16]. Figure 2E shows that PANC-
1 cells form invadopodia (see Figure S3 for all four cell lines), identified
by the colocalization of actin aggregates with areas of focal Matrigel
degradation (white arrows in insert), and that both their basal and EGF-
stimulated focal ECM proteolyses are controlled by NHE1. Analysis of
ECM proteolysis for all four cell lines (Figure 2F) shows that the pattern
of cariporide-dependent inhibition of basal and EGF-stimulated focal
ECM proteolysis closely mirrored its effect on invasive capacity,
demonstrating that, also in PDAC cells, elevated NHE1 activity drives
invadopodia-mediated ECM digestion and invasion.
It is now well acknowledged that NHE1 is required for both normal
and cancer cell migration [27]. However, little is known about the
motile ability of PDAC cells and the signaling events controlling their
motility. Interestingly, motility measured as either total distance
traveled (Figures 2G and S4) or as speed (data not shown) was higher in
the weakly invasive cell line and decreased as invasive ability increased,
suggesting that, in PDAC cells, motility has a minor role in invasion.
This is very much like melanoma cells on basement membrane versus
dermis matrix where they either migrate or invade [30]. Furthermore,
motility showed a differential pattern between the cell lines: the high
basal motility in BXPC3 was strongly stimulated by EGF, and both
basal and EGF-stimulated motilities were dependent on NHE1,
whereas PANC-1 motility was independent of EGF but dependent on
NHE1, and MiaPaCa-2 motility was strongly stimulated by EGF but
independent of NHE1.Altogether, the above data are closely in line with the behavior of
the cells in the orthotopic murine tumor models.
EGFR-NHE1 Regulation of Growth and Invasion
Occurs via a Novel EGFR/NHERF1/NHE1 Signal
Complex
NHERF1 Modulates EGFR Expression and Localization in
Response to EGF Through Ubiquitin-Dependent Proteosomal/
Lysosomal Degradation
In both normal cells and several cancer types, EGFR signaling is
tightly controlled by the scaffolding protein NHERF1 [14,15], and
NHERF1 upregulatesNHE1 activity and invasion in breast cancer [31].
All four cell lines expressedNHERF1 (Figure S5). To assess if NHERF1
regulates the EGFR/NHE1-mediated metastasis by organizing an
EGFR/NHERF1/NHE1 signaling axis, we first measured the response
of EGFR, NHERF1, and NHE1 expression to EGF stimulation in
control and NHERF1-overexpressing PANC-1 cells. In control cells
(Figure 3A, CTR), EGFR expression increased for the first 30
minutes of EGF stimulation and then decreased with longer EGF
stimulation, whereas NHERF1 followed the opposite expression
pattern in that its expression sharply decreased during the initial 30
minutes of EGF stimulation followed by a renewed expression at
longer EGF stimulation times. Furthermore, both the higher
molecular weight fraction of NHE1 and the EGFR phosphorylation,
p(Y1173)-EGFR, increased in response to EGF and with similar
kinetic profiles, resulting in two phosphorylation peaks at 10 and 60
minutes of EGF treatment.
In cells overexpressing exogenous NHERF1 (Figure 3A, WT-
NHERF1), in the absence of EGF, total EGFR expression already
increased, whereas its normalized phosphorylation decreased and it
was internalized in submembrane vesicles. EGF stimulation tended to
increase NHERF1 expression especially at long-term treatment,
which was mirrored by opposite changes in EGFR expression. These
data suggest that the two proteins are engaged in a dynamic regulatory
loop that transmodulates their relative expression levels and activities
in wavelike cycles of expression and degradation (summarized in
Figure 3B).
Because NHERF1 expression can be regulated via proteasomal
degradation [32], we determined if the proteasome is involved in the
above reciprocal dynamics between EGFR and NHERF1. EGF
treatment reduced the total cellular pool of ubiquitinated proteins,
which was reversed by 10 μM of the proteasome inhibitor MG132
(Figure S6), confirming that the activation of the proteasome-
ubiquitin system by EGF could be involved in NHERF1 degradation.
Indeed, as shown in Figure 3C, preincubating PANC-1 cells with
MG132 completely abolished the transient changes of both
NHERF1 and EGFR expression by EGF treatment. Importantly,
long-term EGF treatment increased endogenous NHERF1 expres-
sion, resulting in the downregulation of EGFR expression which was
blocked by MG132 preincubation. Analogously, forced exogenous
NHERF1 overexpression (Figure 3D) was accompanied by a
downregulation of EGFR expression in cells exposed long term to
EGF, and this was reversed by MG132 preincubation which
maintained EGFR in intracellular compartments (summarized in
Figures 3, E and F).
Altogether, these data indicate that EGFR and NHERF1
expression levels are intimately linked in a balanced, dynamic
equilibrium in PDAC via a reciprocal proteosome degradation-
dependent mechanism.
Figure 3. Wavelike, reciprocal regulation of EGFR and NHERF1 expression by EGF is maintained by ubiquitin-mediated degradation
mechanisms. (A) NHERF1, EGFR, p(Y1173)-EGFR, and NHE1 protein levels in basal and EGF stimulated (100 ng/ml) conditions in control
and wild-type (WT) NHERF1-overexpressing PANC-1 cells. Protein loading normalized to β-actin levels. See also Figure S5. (B) Graphs
showing interdependent modulation of EGFR and NHERF1 expression measured (A) during EGF stimulation in control (left panel) and
NHERF10overexpressing (right panel) cells. Error bars, ±SEM (n = 6 experiments). (C, D) Immunofluorescence images of NHERF1 and
EGFR for control (C) and WT-NHERF1 (D)–overexpressing cells. Scale bars, 20μm. See also Figure S6. (E, F) Graphs showing Mg132-
dependent reduction of the EGF-induced modulation of NHERF1 (upper panel) and EGFR (lower panel) expression for control (E) and WT-
NHERF1 (F) cells. Error bars, ± SEM (n = 3 experiments).
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The above data confirm the reciprocal relationship between
activated EGFR and the scaffolding protein NHERF1. The primaryrole of scaffolding proteins is to confer signal specificity and different
biological outcomes by increasing the number of possible protein
interactions via binding to proteins involved in the same signaling
pathway [33]. Therefore, we analyzed the physical/biochemical
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their interaction following EGF stimulation in both control and WT-
NHERF1–overexpressing cells.
In coimmunoprecipitation experiments in PANC-1 cells
(Figure 4A), short-term EGF stimulation (until 30 minutes) increased
the amount of EGFR bound to both NHERF1 and phosphorylated
NHE1 (115-kDa band), thus forming a heterotrimeric EGFR-
NHERF1-NHE1 complex. During a prolonged EGF stimulation
(1 hour and ON), the EGFR-NHERF1 interaction decreased, and
the original heterotrimeric NHE1-NHERF1-EGFR complex pro-
gressed into two distinct subcomplexes: one in whichNHE1was bound
to NHERF1 and another in which the upper, phosphorylated 115-kDa
band of NHE1 was bound to EGFR. Overexpression of exogenous
NHERF1 (Figure S7A) increased the formation of the heterotrimeric
EGFR-NHERF1-NHE1 complex already in the absence of EGF, and
stimulation of these cells with EGF initiated the separation of this
complex into two EGFR-NHE1 and NHERF1-NHE1 interaction
complexes already at a short EGF stimulation (10 minutes), and this
separation increased with EGF incubation time.
These intracellular interaction dynamics were confirmed by laser-
scanning confocal microscopy for EGFR, NHERF1, and NHE1
(Figure 4B). In control cells (only endogenous NHERF1 expression)
and in basal conditions (no EGF, t0), EGFR (blue) was distributed at
both the plasma membrane and in the cytoplasm and showed little
colocalization with either NHERF1 (red) or NHE1 (green). Starting
from 10 minutes of EGF stimulation, pools of the trimeric EGFR-
NHERF1-NHE1 complex appeared in the cytosol and became more
associated with subcortical plasma membrane invaginations (triple
stained, merged in white, arrows) during 30 minutes of EGF
stimulation. That these were plasma membrane invaginations was
confirmed by staining with the rhodamine-conjugated plasma
membrane marker Wheat Germ Agglutinin (Figure 4C, WGA, red).
Between 30 minutes and 1 hour of EGF-stimulation, the trimeric
complex started to segregate into two different subcomplexes composed
of NHERF1-NHE1 (orange areas, asterisks) and NHE1-EGFR (cyan
areas, asterisks). After overnight EGF incubation, the segregation of
NHERF1-NHE1 and EGFR-NHE1 complexes was complete, with
NHERF1-NHE1 being found in smaller, shallower membrane
domains and the EGFR-NHE1 complex in large, membrane rosettelike
caveolae [34] that were strongly positive for both caveolin and WGA
(see Figure S8 for confocal 3D reconstructions where caveolin
colocalized with EGFR and NHE1). This segregation of the transient
EGFR/NHERF1/NHE1 signaling complex into NHE1 containing
dimeric subcomplexes in different lipid raftlike membrane domains
suggests a possible mechanism to give NHE1 specificity toward growth
or invasion.
NHERF1 overexpression (Figure S7B) resulted in its strong
colocalization with the EGFR in submembranous and cytosolic
patches already in basal conditions and a subset of the EGFR-
NHERF1 clusters already colocalized with NHE1 at specific areas of
the plasma membrane. Following 10 minutes of EGF stimulation,
endocytic vesicles carrying EGFR bound to NHE1 (cyan areas,
asterisks) accumulated inside the cells, and with time, the quantity of
EGFR bound with NHERF1 within the cytosol was progressively
reduced, and the amount of NHERF1-NHE1 and EGFR-NHE1
aggregates recycling back to a subplasma membrane compartment
increased (white areas, arrows).
To confirm that these dynamics of EGFR-NHERF1-NHE1 axis
are found in PDAC in vivo, we analyzed their expression patterns byimmunohistofluorescence in pancreatic tumor sections obtained by
implanting the four PDAC cell lines orthotopically in mice
(Figure 4D). In all PDAC-derived tumor sections, when EGFR
staining (blue) was stronger, NHERF1 immunoreactivity (red) was
very low. Moreover, with increasing invasive and metastatic potential,
tumor cells decreasingly expressed the tertiary EGFR-NHERF1-NHE1
complex (seen as white). In close agreement with the in vitro expression
data shown in Figure 4B, in the more aggressive PANC-1– and
MiaPaCa-2–derived tumors, the NHERF1/NHE1 (orange, inset b)
and the EGFR/NHE1 (cyan, inset c) prometastatic subcomplexes were
more common.
Proof-of-Concept Drug Validation Experiments in PANC-1
3D Growth and Invasive Capacity
Combination therapies are being ever more investigated in PDAC to
reduce the effective drug concentrations and the potential risk of
cumulative side effects while increasing antineoplastic effectiveness [20].
As the NHE1 is an integral and essential part of the mechanism by
which the EGFR induces metastatic progression, we hypothesized that
pharmacological inhibition of the NHE1 should potentiate erlotinib
action synergistically at lower concentrations of each agent.
Firstly, we determined the potential of subthreshold concentrations
of cariporide to sensitize PANC-1 3D growth to erlotinib treatment.
As seen in Figure 5A, whereas incubation with 1 μM of either
erlotinib alone or cariporide alone (see 0 μM erlotinib) resulted in no
significant decrease in 3D colony growth, when added together, they
produced a significant inhibition of growth. At higher concentrations,
erlotinib significantly inhibited 3D growth (IC50: 14.3 ± 1.46 μM),
and this inhibition was further increased by coincubation with 1 μM
cariporide (IC50: 3.85 ± 0.51 μM). EGF-stimulated cells were more
sensitive both to erlotinib alone (IC50 5.29 ± 0.47 μM) and to the
cariporide-erlotinib combination (IC50 to 1.08 ± 0.095 μM).
Analysis of these cell growth inhibition curves for the combination
index (CI; [20]) showed that, particularly at the lower doses for
erltoinib, their interaction has a CI of 0.34 and 0.18 in the absence
and presence of EGF, respectively, which indicate strong synergistic
interactions. The CI increased toward values indicative of an additive
relationship at higher erlotinib concentrations. The Dose Reduction
Index (DRI; [20]) can be calculated from these values and is
important in clinical situations because dose reduction would lead to
reduced toxicity toward the patient while maintaining therapeutic
efficacy. Higher DRI values indicate a greater dose reduction for a
given therapeutic effect, and DRIs of 2.6 and 5.2 were calculated in
the absence and presence of EGF, respectively.
We also determined the potential of cariporide to sensitize
invadopodia function to erlotinib treatment in PANC-1 cells
(Figure 5B) and observed that, in non-EGF conditions, only high
concentrations of erlotinib alone had an inhibitory effect on the
activity of the invadopodia, and cariporide greatly further increased
erlotinib’s inhibitory effect. In cells stimulated by EGF, erlotinib
inhibited invadopodia activity already at 5 μM. By itself, cariporide
inhibited invadopodia activity by approximately 50% and 75% in the
absence or presence of EGF, respectively, and cariporide further
increased erlotinib-dependent inhibition of invadopodia function in
an additive manner.
Discussion
Because of the very low success rate of new molecules together with
the long insertion time for a successful molecule, an important aspect
Figure 4. AnEGFR/NHERF1/NHE1protein-protein axis is activatedbyEGFRstimulation. (A) Coimmunoprecipationwith EGFRorNHE1during
EGF stimulation. (B) Subcellular distribution of EGFR (blue), NHERF1 (red), and NHE1 (green) in PANC1 cells by confocal analysis. Arrows
indicate areas of EGFR/NHERF1/NHE1 colocalization (white), and asterisks indicate EGFR/NHE1 colocalization (cyan), whereas NHERF1/
NHE1 colocalization is in orange. There are significant overlapping in NHERF1, NHE1, and EGFR signals at 30minutes of EGF stimulation and
a segregation of the NHE1-EGFR and NHE1-NHERF1 complexes already at 1 hour of EGF stimulation. Data are representative of four
independent experiments. Scale bars, 20 μm. See also Figure S7. (C) Subcellular distribution of WGA-labeled plasmamembrane, EGFR, and
NHE1 in PANC-1 cells by confocal analysis. XY and XZ axis images are shown. Scale bars, 20 μm for micrographs, 10 μm for inset. See also
FigureS8. (D) Immunohistofluorescence for EGFR,NHE1, andNHERF1andhematoxylin and eosin staining in pancreatic tissues derived from
mice in which the four PDAC cell lines were orthotopically implanted. Areas of EGFR/NHERF1/NHE1, EGFR/NHE1, and NHERF1/NHE1
colocalization are in white (insets labeled a), cyan (insets labeled c), or orange (insets labeled b), respectively. Scale bars, 100 μm.
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Figure 5. Subthreshold inhibition of NHE1 by cariporide synergistically potentiates erlotinib-dependent inhibition of 3D growth and
invadopodia. All experiments were conducted in PANC-1 cells in the absence or presence of 100 ng/ml EGF with 1 μM cariporide and in
increasing erlotinib concentrations. (A) 3DMatrigel growth as in Figure 2. Mean ± SEM, unpaired Student’s t test. *P b .05, **P b .01, and
****P b .0001 compared with the control cells and †P b .01, ††P b .001, and †††P b .0001 compared with the respective EGF cells for each
line. (B) Invadopodia activity measured as in Figure 3. Mean ± SEM, unpaired Student’s t test. **P b .01 and ***P b .001 compared with
the control cells and †P b .01, ††P b .001, and †††P b .0001 compared to the respective EGF cells for each line.
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molecules that have already passed FDA approval [18]. This will
significantly reduce the time to clinical use. A further important
consideration in testing repurposed molecules is to find targets that
are just upstream of the phenotypic metastatic response and that
integrate the various signaling pathways downstream of the primary
signal which lead to the final phenotypic response. Here, the EGFR
represents a prototypical molecule, as its signal is propagated through
a complex network involving cross talks, nodes, and feedback loops
with parallel pathways [35] and implies that a combination of an
EGFR inhibitor with molecules targeting final components of the
ramified signaling pathways downstream of the receptor may offer a
novel approach to controlling PDAC metastasis.
For many receptor tyrosine receptors, the NHE1 has been
demonstrated to be such a protein. Although it is activated by and is
an important effector of the EGFR in both normal tissues and in a series
of tumor types (for reviews, [16,27], its role in transducing the EGFR
signal to regulate PDAC hallmark metastatic behaviors is still
undescribed. Therefore, we evaluated the role and mechanism of
interaction ofNHE1 inEGFR-driven PDACmetastatic progression and
the potential use in combination with erlotinib of its specific inhibitor,
cariporide, which has already passed phase III clinical trials. Indeed,
herein we describe a novel EGFR-NHE1 signaling cassette involved in
the EGFR-driven increases in metastatic potential in PDAC.
Using the EGAN data mining program to determine genome
interaction networks from a collection of mRNA isolated from a series
of patients’ normal and tumor tissue and PDAC cell lines, we found that
theNHE1 is an important component of the EGFRnetwork in PDAC.
This result is complementary to that obtained when interrogating the“Search Tool for the Retrieval of Interacting Genes/proteins” for
interactions with EGFR. Interestingly, there were a large number of
other pH-regulating transporters and enzymes that are also associated
with the EGFR in PDAC tissues, supporting a fundamental role for pH
regulation in the desmoplastic compartment.
This EGFR-NHE1 relationship and its dynamics in driving PDAC
progression were subsequently verified in a series of four PDAC cell lines
representing different stages of progression and comprising two recently
described PDAC subtypes, the “classical” (CAPAN-2 and BXPC3) and
“quasimesenchymal” (PANC-1 and MiaPaCa-2) types [9]. EGF
stimulated NHE1 activity in all the PDAC cell lines, and the specific
NHE1 inhibitor cariporide inhibited both the basal and EGFR-driven
increase in 3D colony growth, invasion, and invadopodia proteolytic
function. This strong functional dependence on NHE1 activity was
observed in both the “classical” and “quasimesenchymal” cell types, and
this common inhibitory response to cariporide is important in PDAC
because various drugs [9] and drug combinations [36] function quite
differently in the two different PDAC subtypes.
An important finding of this study was that, in PDAC, the EGFR
promotes malignant cell behavior not only via the canonical MAPK
or PI3K-AKT signal cascades [37] but also via a novel protein-protein
complex centered around EGFR, NHE1, and the scaffolding protein
NHERF1. Within this complex, NHERF1 is engaged in a highly
dynamic negative feedback regulatory mechanism with EGFR in
which their expression levels are reciprocally downregulated via
ubiquitin-dependent proteosomal/lysosomal degradation. Specifical-
ly, in this regulatory circuit, EGF-activated EGFR functions as a
negative regulator of NHERF1 expression by committing NHERF1
to proteosomal degradation (Figure 3), and NHERF1 functions to
Figure 6. Mechanism of dynamics of the EGFR-NHERF1-NHE1 signaling axis and its role in PDAC growth and invasion.In control cells
EGFR, NHERF1, and NHE1 are separate. Short-term EGF stimulation (0-30 min) induces a transient, trimeric, EGFR-NHERF1-NHE1
complex, which segregates into two dimeric complexes (EGFR-NHE1 and NHERF1-NHE1) after prolonged EGF-stimulation. Upon EGF
stimulation, NHERF1 expression decreases via proteosomal degradation, and EGFR is internalized and trafficked to intracellular vesicles
by associating with the remaining NHERF1. From endosomes, a minor part of EGFR (≈40%), bound to NHERF1, is rapidly recycled back
to the cell surface (30 minutes of EGF stimulation) where EGFR, NHERF1, and NHE1 are recruited together in a EGFR-NHERF1-NHE1
complex, whereas the remaining endosomal EGFR (≈60%) is destined to lysosomal degradation at longer EGF stimulation. This process
avoids new cycles of plasma membrane (PM) receptor stimulation; permits an increase in the PM abundance of NHERF1, whose cellular
expression is balanced by EGFR expression levels; and, importantly, favors the segregation of the trimer complex in two subcomplexes
residing in specific regions of the PMwhere polarized NHE1 signaling occurs: the EGFR-NHE1 subcomplex is retained in caveolae and the
NHERF1-NHE1 subcomplex in a different subset of PM invaginations. In this scenario, this branch point in the EGFR signaling pathway
leading to NHE1 signal diversification and specificity may account for PDAC’s partial response to erlotinib and could explain why NHE1
inhibition with cariporide is important for combination therapy with erlotinib but also an important independent therapeutic approach in
PDAC. Indeed, panels (A), (B), and (C) show the hypothetical effect of treatment with erlotinib (erl), 1 μM cariporide (Car), and both
inhibitors, respectively, on long-term signaling and metastatic function. The size of the signal indicates the amplitude of the “residual”
signaling from the different NHE1-containing subcomplexes.
164 NHE1 Is Essential in EGFR-Driven PDAC Progression Cardone et al. Neoplasia Vol. 17, No. 2, 2015regulate the duration of the EGFR signal by inducing receptor
internalization and its rapid recycling to the plasma membrane after a
short EGF stimulation while sorting the majority, but not all, of the
EGFRs to lysosomal degradation after a persistent EGF stimulation
(Figures 3 and 4). Interestingly, this interdependent threshold-controlled regulation of EGFR and NHERF1 expression is
mechanistically coupled to the formation of a trimeric EGFR-
NHERF1-NHE1 complex at short-term EGF stimulation, whereas
long-term EGF stimulation redistributes these three complexed
proteins into EGFR-NHE1 complexes in very large caveolae
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membrane invaginations (model in Figure 6). This suggests that
these two pools of NHE1 signaling in different PM regions may
provide signals for differentiation of NHE1 function, which
independently promotes ECM digestion, local invasion, and 3D
growth. Importantly, in tumor tissues from mice in which the four
PDAC cell lines were orthotopically implanted, this segregation into
separate EGFR-NHE1 and NHERF1-NHE1 plasma membrane
districts increased progressively with the aggressiveness of the tumor
(Figure 4D).
These data are in line with studies reporting that EGFR can also
control cellular processes through 1) its ability to physically interact
with other proteins independently of its kinase activity or ligand
activation [38], 2) its compartmentalization within plasma mem-
brane lipid rafts in clusters with its signaling molecules, and 3) its
endocytosis [39]. Interestingly, lipid raft localization of EGFR
correlates with its hyperactivation [40], resistance to tyrosine kinase
inhibitors [41], and the ability to modulate its partner’s signaling
properties [42]. In this way, the magnitude and efficiency of the
receptor communication to its effectors are dictated both by the
duration of receptor activation, which is controlled by the kinetics of
its membrane trafficking, and by the receptor's proximity to its
downstream effectors, which is ensued by their spatial colocalization
within the same receptor endocytic pathway [43]. It has been
demonstrated that modifying this temporal and spatial regulation of
the EGFR alters signaling [44].
We lastly explored the utility and kinetics of cariporide as a
combination therapy with erlotinib on 3D colony growth and invasive
capacity. PANC-1 cells were chosen because they are reported to be the
most resistant of these cell lines to erlotinib [12,45]. Importantly, a
subthreshold concentration of cariporide, which alone did not affect 3D
growth, synergistically enhanced erlotinib-dependent inhibition of 3D
colony growth especially at low erlotinib concentrations. In the absence
of EGF, erlotinib had very little effect on invasive capacity at low
concentrations, whereas in the presence of EGF, both erlotinib and
cariporide singly and their combination displayed increased inhibition
especially at low erlotinib concentrations. This erlotinib insensitivity of
invasive capacity in the absence of ligand activation of the EGFR
accentuates the importance of the use of cariporide to help improve
clinical response, as it suggests that cariporide per se will also give an
important increased therapeutic response well beyond its effect on
growth. As cariporide has successfully finished clinical trials, there is the
possibility for a rapid translation of this therapeutic strategy to the
PDAC clinical setting.
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